Skip to main content
CRSP
NASDAQ Life Sciences

CRISPR Therapeutics Reports Q4 & FY25 Results, Highlights Strong CASGEVY Uptake & Pipeline Progress

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$49.79
Mkt Cap
$4.663B
52W Low
$30.04
52W High
$78.48
52W Position info
66% above low
Off High info
37% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

CRSP sits 66% above its 52-week low of $30.04.

Summary

CRISPR Therapeutics announced its Q4 and full-year 2025 financial results, reporting $116 million in annual CASGEVY revenue and significant progress across its broad gene-editing pipeline, including new clinical trial initiations.


Key Events · Earnings and Guidance · CRSP

  • Strong CASGEVY Revenue Growth

    Reported $54 million in Q4 2025 and $116 million in full-year 2025 revenue for CASGEVY, with patient initiations nearly tripling compared to the prior year.

  • Robust Pipeline Progression

    Advanced multiple gene-editing programs, including CTX460, CTX340, and CTX213, with several new clinical trial initiations anticipated in H1/mid-2026.

  • Widened Net Loss

    Reported a net loss of $130.6 million for Q4 2025 and $581.6 million for the full year, primarily due to increased collaboration expenses, while maintaining a strong cash position of $1.97 billion.

  • FDA Priority Voucher

    Received an FDA Commissioner's National Priority Voucher for pediatric CASGEVY submissions, expected to commence in the first half of 2026.


Analysis · CRSP · Life Sciences

The report provides a comprehensive update on CRISPR Therapeutics' financial performance and extensive pipeline. While the company reported a widened net loss for Q4 and FY2025, primarily due to increased collaboration expenses, its cash position remains robust. A key highlight is the commercial ramp-up of CASGEVY, which generated $116 million in full-year revenue, with patient initiations nearly tripling in 2025. The company also detailed advancements across its in vivo liver editing, siRNA, autoimmune, immuno-oncology, and regenerative medicine programs, with several new clinical trial initiations anticipated in the first half of 2026. The FDA's award of a National Priority Voucher for pediatric CASGEVY submissions further underscores regulatory progress.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CRSP was trading at $49.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $30.04 to $78.48. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRSP - Latest Insights

CRSP
Nov 10, 2026, 1:48 PM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $45.48
Real-time Price: $39.50 info
Change: -$5.98 (-13%) info
Market Cap: $3.793B info
CRSP
Nov 09, 2026, 9:16 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $50.42
Real-time Price: $39.50 info
Change: -$10.92 (-22%) info
Market Cap: $3.793B info
CRSP
Nov 02, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $49.98
Real-time Price: $39.50 info
Change: -$10.48 (-21%) info
Market Cap: $3.793B info
CRSP
Nov 02, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $49.01
Real-time Price: $39.50 info
Change: -$9.51 (-19%) info
Market Cap: $3.793B info
CRSP
Nov 02, 2026, 4:06 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $49.01
Real-time Price: $39.50 info
Change: -$9.51 (-19%) info
Market Cap: $3.793B info